BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Mura VL, Tosetti G, Primignani M, Salerno F. Use of non-selective beta blockers in cirrhosis: The evidence we need before closing (or not) the window. World J Gastroenterol 2015; 21(8): 2265-2268 [PMID: 25741132 DOI: 10.3748/wjg.v21.i8.2265]
URL: https://www.wjgnet.com/1007-9327/full/v21/i8/2265.htm
Number Citing Articles
1
Carlo Merkel, Aleksander Krag. Portal Hypertension VI2016; : 187 doi: 10.1007/978-3-319-23018-4_20
2
Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot StudyGut and Liver 2017; 11(5): 702 doi: 10.5009/gnl16478
3
Alana Zulian Terres, Rafael Sartori Balbinot, Ana Laura Facco Muscope, Morgana Luisa Longen, Bruna Schena, Bruna Teston Cini, Gilberto Luis Rost, Juline Isabel Leichtweis Balensiefer, Louise Zanotto Eberhardt, Raul Angelo Balbinot, Silvana Sartori Balbinot, Jonathan Soldera. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortalityGastroenterología y Hepatología (English Edition) 2022; 45(1): 25 doi: 10.1016/j.gastre.2021.02.009
4
Alana Zulian Terres, Rafael Sartori Balbinot, Ana Laura Facco Muscope, Morgana Luisa Longen, Bruna Schena, Bruna Teston Cini, Gilberto Luis Rost, Juline Isabel Leichtweis Balensiefer, Louise Zanotto Eberhardt, Raul Angelo Balbinot, Silvana Sartori Balbinot, Jonathan Soldera. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortalityGastroenterología y Hepatología 2022; 45(1): 25 doi: 10.1016/j.gastrohep.2021.02.007